Clinical Trial Search

Primary: Occurrence of Intradialytic Hypotension (Intradialytic Hypotension Defined as Nadir Systolic BP <90 mmHg) — 578; 571 Number of occurrences — p=0.5

Primary: AUC0-∞ of Eculizumab — 104346442.41; 114291981.79 (ng/ml)*hour

Primary: Injection Pain — 44.5; 30 units on a scale

Primary: Proportion of Risky Drinkers Measured by AUDIT-C — 20; 39 Participants

Primary: Percentage of Subjects With at Least One Episode of Shigellosis According to the Protocol Primary Case Definition — 46.9; 42.9 Percentage of subjects — p=0.4266

Primary: Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients — 80.6; 15.9 mcg/mL

Primary: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) — 47 Participants

Primary: Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index — 74.0; 66.4 Percentage of Participants — p=0.0782

Primary: Change From Baseline in HbA1c at 24 Weeks (Part 1) — 8.23; 8.10; 8.07; 8.38 Percentage of glycosylated hemoglobin

Primary: Progression Free Survival (PFS) — 53 percentage of participants

Primary: Labor Market Participation in Ordinary Paid Employment, or Education. — 83; 49 Participants

Primary: Change From Baseline in Monthly Migraine Days (Weeks 1-12) — -4.3; -3.9; -4.1; -3.1 Migraine Days — p=0.0001

Primary: Absolute Change From Baseline in Percent-predicted Forced Expiratory Volume in One Second (ppFEV1) at Week 48 — -1.396; -1.992 Percentage of predicted FEV1 — p=0.5336

Primary: Effects of Co-administration of Tesofensine/Metoprolol Treatment vs. Placebo on 24-hour Mean Heart Rate — 67; 70 beats per minutes (BPM) — p=0.004

Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants